|
Panacea Biotec introduces anti-allergy drug
EPP News Bureau - Mumbai
Panacea Biotec has launched Ralif (rupatadine 10 mg), novel anti-allergy drug
for the management of diseases with allergic inflammatory conditions, such as
seasonal and perennial allergic rhinitis.
According to the company release, Ralif, a non-sedating orally active dual antagonist
of histamine and platelet-activating factor (PAF) represents a novel approach
for the treatment of allergic rhinitis. Ralif provides effective relief from
allergy by inhibiting histamine & PAF, the most common mediators involved
in allergic rhinitis.
Rajesh Jain, joint managing director, Panacea Biotec Ltd says, ‘‘Ralif
has a dual mechanism of action which provides better relief from both allergy
and associated inflammation whereas currently available molecules for allergic
rhinitis have antihistaminic property only.’’
Ralif has rapid onset of action which provides faster relief. Ralif does not
cause sleepiness and its long-lasting effect permits convenient once a day dosage.
Ralif can be prescribed for the management of allergic and inflammatory symptoms,
such as nasal congestion, nasal itching and running nose, sneezing and inflammation,
conjunctival itching, pharyngeal itching. Ralif can also be used to treat patients
with chronic urticaria, a type of allergic skin rash, the release added.
Allergic rhinitis affects about one in ten people and is one of the most common
allergic conditions. Allergic rhinitis can cause sleeplessness, fatigue and
irritability that affect performance at work or school, and increase the risk
of developing more serious allergic conditions such as asthma.
|
Panacea Biotec Ltd has increased
its dividend to 150 per cent (ie. Rs 1.50 per share) on equity shares
of the company, for the financial year 2004-05. The company has also paid
dividend of 12 per cent (pro-rate) on 12 per cent preference shares redeemed
during the year and 4.5 per cent as interim dividend on 4.5 per cent Preference
Shares.
The company decided to re-issue
1.49 lakh forfeited shares to some director(s)/officer(s) of the company
for the purpose of sale in the open market through recognised stock exchanges
having nation-wide presence and reimburse the net amount received on such
sale, to the company’s account.
The company achieved a smart
growth in profitability during the year ended March 2005. The company’s
standalone net profit moved up by 82.8 per cent to Rs 30.06 crore from
Rs 16.44 crore in the previous year. The net sales improved by 24.4 per
cent to Rs 325.54 crore from Rs 261.62 crore.
With the smart improvement
in profitability its earning per share of Re one each face value improved
to Rs 4.63 from Rs 2.72 in the preceding year.
|
|
